The Fifth China International Import Expo was held from November 5 to 10 in Shanghai. The Fair **** from 127 countries and regions to participate in the business exhibition, 66 countries and three international organizations in the national exhibition, the number of more than the previous year.
After four successful sessions, the Fair has become an important "window" for new products and technologies from around the world to enter the Chinese market. According to the statistics of the Ministry of Commerce, in the first four sessions of the Fair, exhibitors released more than 1,500 new products, technologies and services, and the cumulative turnover amounted to more than 270 billion U.S. dollars.
Taking the Fair as a bridge, in recent years, many multinational enterprises have been deepening local cooperation, accelerating the introduction of innovations, promoting products from the "four-leaf clover" to the market, and realizing the "exhibits into commodities", and a series of cutting-edge innovations from all over the world have boarded the "fast track" to enter China. The company is also working on a series of global cutting-edge innovations to enter the "fast lane" of China.
Multinational enterprises plowing into the Chinese market
The Daily Economic News reporter noted that, among the multinational enterprises exhibiting in the exhibition, there are many pharmaceutical and medical enterprises have ushered in an important anniversary of their entry into the Chinese market this year. For example, Siemens Healthcare, which opened for business in Shanghai in 1992, and Medtronic and Thermo Fisher, which are celebrating their 40th anniversary of entering the Chinese market.
1992 was the starting point of China's healthcare system reform, and the opening of Siemens Medical Devices Shanghai in 1992 marked the beginning of Siemens Healthcare's 30-year history of research and development and production of medical devices in China. Since the production of the first CT equipment in 1992, X-ray equipment in 2004 and ultrasound equipment in 2022, Siemens Shanghai Medical Equipment Co., Ltd. has been expanding its production lines and business, covering the R&D, manufacturing and customer service of CT, X-ray, mobile C-arm, ultrasound, digitalized healthcare and automation. To date, the cumulative shipment of medical equipment produced by Shanghai has exceeded 40,000 units, making it one of the largest R&D and production bases of Siemens Healthcare worldwide.
While developing its own business, Siemens Healthcare also focuses on cultivating quality local suppliers. From the initial promotion of comprehensive localization of parts supply, to the continuous attempts to **** with local suppliers to develop parts with higher technological content, to enhance the innovation ability of local suppliers, and to further strengthen the competitiveness of the local supply chain. At present, the localization rate of the company's supply chain exceeds 80%.
In June this year, Siemens Healthcare China announced a new localization strategy of "National Intelligence Innovation" to further strengthen its roots and services in China. Now, the road ahead is even clearer - we believe that under the guidance of the localization strategy of 'National Intelligence and Innovation', Siemens Shanghai Medical Devices Ltd. will make a brand new start and open up another brilliant chapter by upgrading the high-end manufacturing capability, enhancing the strength of independent R&D, and perfecting the construction of local supply chain," said Mr. Wang. and improve the local supply chain, opening up another brilliant chapter." said Mr. Wang Hao, President of Siemens Healthcare Greater China.
The year 2022 also marks the 40th anniversary of Thermo Fisher's official entry into China. Since the establishment of its first sales office in China in 1982, Thermo Fisher has been working side by side with its industry counterparts upstream and downstream to promote the construction of the local industrial ecosystem, support the country's high-quality development, and help the society **** the same progress with cutting-edge technologies and innovative solutions "customized in China". At the Expo, Thermo Fisher is also presenting its 40th anniversary theme exhibition area to tell the story of how it has continued to increase local investment and practice localization strategy in China over the years.
"The success of the five consecutive sessions of the Fair has demonstrated the strong resilience of China's economy and the size of its mega-market, and has further strengthened Thermo Fisher's commitment to 'Rooted in China, Serving China'." HannPang, President of Thermo Fisher China, said, "This year marks the 40th anniversary of Thermo Fisher's official entry into China, and the fifth consecutive time that Thermo Fisher has participated in the Fair. As a global leader in empowering scientific and technological progress, Thermo Fisher will use this platform to continuously integrate the world's leading science and technology and innovations into localized practices, and join hands with the government and partners from all walks of life*** to promote the construction of the local industrial ecosystem and make the world healthier, cleaner and safer."
The Fair welcomes new faces
In addition to companies that have been in the domestic market for many years and have participated in the event for many consecutive years, this year's Fair also welcomes some new faces. For example, after splitting from Merck Sharp & Dohme last year, Ocalon made its debut at the fair as an independent operating company. In addition, in 2020, the third session of the fair, just acquired by AbbVie 63 billion U.S. dollars, Allergan Aesthetics had its first exhibition; now, Allergan Aesthetics and the parent company AbbVie *** with the fifth session of the fair, in order to further demonstrate its heavyweight products and corporate strategy.
In its debut at the Fair, Ocalon will focus on the innovative layout of "full reproductive cycle" and "full life cycle" protection for women and their families, and comprehensively display diversified innovations and solutions in the two business areas of women's health and classic brands.
This year's event will showcase the innovative layout of the "Total Birth Cycle" and "Total Lifecycle" protection for women's health and classic brands.
At this year's Fair, Ovaltine's debut products are closely related to women's health, including "fertility-friendly" contraceptive choices - the only single-root subcutaneous implant contraceptive product approved in China, etrogestrel implant, and a new long-acting ovulation enhancer for assisted reproduction, as well as a new type of long-lasting ovulation enhancer for women's health. Elonva (corifollitropinalfa), a new long-acting ovulation stimulation injection for assisted reproduction, and an innovative medical (002173) device for the treatment of postpartum hemorrhage.
Ocalon plans to introduce the innovative medical devices to China as soon as possible to help Chinese women and medical professionals better cope with this life-threatening childbirth complication. The booth also showcased for the first time the "Birth Friendly Community of the Future", which is designed to bridge the "last kilometer" of the centralized strategy in the community and the family, through the concept of "Education - Assessment - Intervention".
In recent years, the government of China has been working on the development of a "fertility-friendly future community".
In recent years, consumer demand for medical aesthetics has shown growth, and the medical aesthetics industry has become one of the hottest tracks in the medical health industry. At the Expo, Allergan Aesthetics will not only showcase cutting-edge innovative products, but also share insights and trend research results on the entire Chinese medical aesthetic industry, and jointly organize a series of medical aesthetic science and education activities with its upstream and downstream partners to help raise public awareness of medical aesthetics and help build a good medical aesthetic ecosystem.
In addition, the shortage of medical beauty professionals has been restricting the development of the industry. "At this year's Expo, we have more initiatives to promote the industry's talent training, and we hope to use the Expo to show the medical aesthetic industry to all sectors of the community, and continue to advocate the standardized development of the industry." Qiu Hanhua, general manager of Allergan Aesthetics China, said that the Allergan Aesthetics Shanghai Innovation Center has recently been inaugurated, and plans to provide 2,500 to 3,000 trainings for professional medical aesthetics doctors every year.
Significant spillover effect of the Fair
In 2018, MediTech exhibited at the first edition of the Fair as the only radiotherapy company, and has been exhibiting for five consecutive years now. After witnessing the spillover effect of the Expo platform for the first time, MediTech has become more and more determined to plough into the Chinese market. The company set up its regional headquarters in Shanghai in 2018, completing the upgrade of its role from an exhibitor to an investor, and accelerating the landing of international cutting-edge radiotherapy technology in the Chinese market. In 2022, the 50th anniversary of MediKarma's global presence and the 40th anniversary of its entry into the Chinese market, MediKarma will make its fifth appearance at the Fair with its world-leading precision radiotherapy smart solutions, practicing the "Healthy China 2030" strategy with its customers and partners in the industry***.
This year's Fair, MediTech's innovative solutions include HarmonyPro, the world's first new-generation intelligent and precise radiotherapy solution, which injects new momentum into the intelligent, precise and digital development of the radiotherapy industry through the comprehensive upgrading of the three major dimensions of intelligent, full-process and adaptive; ElektaStudio, China's first integrated image-guided brachytherapy solution; and ElektaStudio, the first integrated image-guided brachytherapy solution in China, which provides the most accurate and precise radiotherapy treatment. ElektaStudio, which integrates the Flexitron brachytherapy platform, the OncentraBrachy treatment planning system, the applicator and the ImagingRing mobile CT system, and can one-stop realize the full-process image-guided brachytherapy in various aspects such as applicator insertion, position verification, treatment plan design and treatment implementation. The ImagingRing mobile CT system is a one-stop solution for image-guided brachytherapy in all phases of the treatment process, including applicator placement, position verification, treatment plan design, and treatment delivery, without the need to move patients.
In addition, the mobile design facilitates access to any treatment room in the hospital and enables real-time imaging, providing physicians with patient images for all aspects of the brachytherapy process, including high-quality images for plan design and low-dose imaging for treatment guidance and quality control, which not only eliminates the need to transfer patients back and forth from the treatment room to the CT suite, but also avoids the need to shift the applicator as a result of the transfer. This not only eliminates the need to transport patients from the treatment room to the CT room, but also avoids the displacement of the source device caused by the transfer, which improves treatment accuracy and enhances diagnostic and treatment efficiency.
In addition to the first exhibition of products, this year's Fair, the high-field magnetic **** vibration gas pedal integrated radiotherapy system ElektaUnity debuted in Hall 6.2 of the integrated exhibition area. ElektaUnity subversive medical linear gas pedal and 1.5T high-field magnetic **** vibration collection in the same platform, through the magnetic *** vibration of high-resolution imaging in real time tracking of tumors, the formulation of online adjustment of the treatment plan, thus achieving efficient, effective, and efficient treatment. Adjustment of the treatment plan, thus realizing efficient and personalized online adaptive radiation therapy. Since serving Chinese patients in April 2020, ElektaUnity has treated more than 1,000 Chinese tumor patients, bringing a leading reference for localized clinical diagnosis and treatment, and implying a new level and more possibilities for tumor radiation therapy in China.
As an old friend of the Fair for four consecutive years, Boston Scientific has witnessed the development and growth of the Fair, and has continued to take advantage of the spillover effects of this high-level platform for opening up to the outside world, and has realized the transformation of a number of innovative medical technologies from exhibits to commodities. A number of innovative medical technologies have realized the transformation from "exhibits to commodities". Boston Scientific also ushered in an important breakthrough in local production and research this year. This year, Boston Scientific successfully registered Boston Scientific Medical Technology (Shanghai) Co., Ltd. with a view to further accelerating the local integration in the areas of production, transformation, innovation incubation and other areas beyond trade.
In July 2020, Boston Scientific Polaris Intravascular Ultrasound System was successfully piloted for local production, and the product was formally granted a registration certificate by the State Drug Administration in July 2022. In September 2022, the first Polaris Intravascular Ultrasound System was rolled out of the Jabil plant in Shanghai, which marked the first Chinese-produced, local-supplied Boston Scientific product to officially land, opening the way for Boston Scientific to further accelerate local integration in areas other than trade. In September 2022, the first Polaris endovascular ultrasound system was rolled out of the Jabil plant in Shanghai, marking Boston Scientific's first product manufactured in China and supplied locally.
To address the high incidence of thyroid nodules in China, Boston Scientific's Chinese R&D team developed an ablation device, the "Fusion Wing" single-use radiofrequency (RF) ablation electrode, and in September 2022, this locally-developed, locally-produced product successfully completed its first thyroid nodule ablation case. In September 2022, this locally developed, locally manufactured product successfully completed its first thyroid nodule ablation procedure for the benefit of Chinese patients. This is Boston Scientific's first truly Chinese-developed, Chinese-manufactured medical device.
Standing on the node of "the first year of localization", Boston Scientific brought more than 60 exhibits, nearly half of which are unlisted products in China, covering the five major areas of cardiac health, peripheral vascular health, digestive and respiratory health, urological health, and oncology prevention and treatment, and a number of innovative products were unveiled.
In addition, Boehringer Ingelheim stroke total solutions will be presented at two consecutive sessions of the Fair from 2019 to 2020. At the 4th Fair, Boehringer Ingelheim and Wenjiang District Government of Chengdu City reached a cooperation to invest in the construction of a German Gold Standard Stroke Rehabilitation Center in Chengdu Medical City, Sichuan Province, and the project includes Jida Rehabilitation Offline Physical Rehabilitation Center and Jida Rehabilitation Internet Hospital. The project in the fifth session of the Fair during the debut results, so that the concept of "total stroke solution" has become a stroke rehabilitation hospital and Internet rehabilitation hospital to benefit the people. During the last Fair, the project was selected as a representative case of the spillover effect of the Fair in the "Pavilion of China's accession to the WTO in 20 years", and will be highlighted in the "Exhibitors to Investors" exhibition area of the Fair.
Many companies are concerned about the "dual-carbon" goal
It is worth mentioning that this year, a number of multinational corporations have also expressed their concerns about the "dual-carbon" goal.
In 2021, Thermo Fisher announced its global carbon emissions goal of achieving net-zero carbon emissions by 2050. Over the past 40 years of its presence in China, Thermo Fisher has continued to focus on local ecological health, integrating cutting-edge innovations and holistic solutions into local sustainable development practices, and helping to realize the goal of "carbon peaking and carbon neutrality". Taking this as an opportunity, Thermo Fisher will launch its sustainable development project - the future ecological device "*** Ecology" on the site of this year's Fair. As the finale of the 40th anniversary series of activities, the device extracts environmental samples from different locations in Shanghai, and with the help of Thermo Fisher's life science laboratory equipment and technology, visualizes the ****-biological relationship of the micro-systems in the samples, to further stimulate the public's attention to sustainable development and ecological health.
Sustainability has been a guiding principle in Boehringer Ingelheim's DNA since its founding in 1885, and in 2021, the company formally launched its "Sustainability for Generations" strategy, which integrates all initiatives to address health, economic, social, and environmental challenges into a global, collaborative network. In 2021, the company officially launched its "Sustainability for Generations" strategy, which integrates all initiatives to address health, economic, social and environmental challenges into a global, collaborative network that contributes to a sustainable world and a healthier future. Boehringer Ingelheim actively promotes the green and low-carbon transformation of the biopharmaceutical industry and contributes to the industry's high-quality development.
The Boehringer Ingelheim booth at the 5th Fair was designed and constructed with the concept of green and sustainable development in mind. The main booth, themed "Tree of Life", was designed around the concept of green and sustainable development. The materials selected for the booth are based on the 6R concept and follow the principle of recycling. The use of recyclable finishing materials not only achieves a 100% recycling rate, but also reduces waste and pollutants as much as possible. At the same time, high-quality sound and light equipment with no noise, reduced volume and low power consumption are used to save energy and reduce consumption. The booth showcases Boehringer Ingelheim's latest achievements in sustainability, including the first carbon-neutral plant in China's pharmaceutical industry to be certified by domestic and international authorities.